TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Different Ventilation Strategies in Children Using the Proseal™ Laryngeal Mask Airway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical classification 1,2 (Healthy or relatively healthy children)~* Subjects scheduled for outpatient surgical procedures.~* Surgical procedure anticipated to be \< 90 minutes~* Subject weight of ≤ 20 kg (44 lbs)~* Subject age of 12 months to 5 years (inclusive)~Exclusion Criteria:~* Inpatient~* ASA physical classification of 3, 4 or E (sick children)~* Risk of aspiration~* Subjects with malignant hyperthermia or family history of malignant hyperthermia~* Subjects with tracheostomies

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Spontaneous ventilation (Type: EXPERIMENTAL): Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
- Pressure support ventilation (Type: EXPERIMENTAL): Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
- Pressure control ventilation (Type: ACTIVE_COMPARATOR): Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries during a one month period with expected post operative hospital admission~Exclusion Criteria:~* Allergy to Ketamine~* History of narcotic abuse or dependence~* Those patients for which decreased cognitive function is a barrier to accurate data collection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
- Saline (Type: PLACEBO_COMPARATOR): Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Adductor Canal Block With and Without Dexamethasone for Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ASA I-II Arthroscopic anterior cruciate ligament reconstruction~Exclusion Criteria:~* patient refusal~* drug allergy~* failed procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group I (Type: ACTIVE_COMPARATOR): Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
- group II (Type: ACTIVE_COMPARATOR): Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a positive BCL2/IgH rearrangement in peripheral blood (PB) and/or bone marrow (BM)~* clinical stage III or IV, requiring treatment with one or more of the following criteria: symptoms related to the disease, hemoglobin less than 12 g/dL, platelets less than 100 G/L, progressive disease, bulky tumor of more than 10 cm~Exclusion Criteria:~* pretreatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.~2. Infants who are entering their first full RSV season at the time of screening.~Key Exclusion Criteria:~1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.~2. Any fever (\>= 100.4°F \[\>= 38.0°C\], regardless of route) or lower respiratory illness within 7 days prior to randomization.~3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.~4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.~5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 365 Days
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
- MEDI8897 50 mg (Type: EXPERIMENTAL): Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult patients aged 18\~70 years.~2. Patients receiving cardiac surgery with cardiopulmonary bypass~3. Written Informed consent obtained~Exclusion Criteria:~1. Acquired chromatic disorder~2. Active intravascular coagulation~3. Previous convulsion or seizure~4. Allergy or contraindication to tranexamic acid injection or its components~5. Feeding or pregnancy women~6. Terminal illness with a life expectancy of less than 3 months~7. Patients with mental or legal disability~8. Currently enrolled in another perioperative interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic Acid Dosage 1 (Type: EXPERIMENTAL): A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
- Tranexamic Acid Dosage 2 (Type: ACTIVE_COMPARATOR): A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Participants with asthma who completed the treatment period in the previous dupilumab asthma clinical study LTS12551.~* Signed written informed consent.~Exclusion criteria:~* Participants who experienced any systemic hypersensitivity reactions to the investigational medicinal product in the previous dupilumab asthma study LTS12551, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab might present an unreasonable risk for the participant.~* Clinically significant comorbidity/lung disease other than asthma.~* Participants with active autoimmune disease or participants who, as per Investigator's medical judgment, were suspected of having high risk for developing autoimmune disease.~* History of malignancy within 5 years before enrollment except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dupilumab (Type: EXPERIMENTAL): Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (\>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid \[OCS\] for those participants from the original parent study EFC13691 \[NCT02528214\]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* pregnancy at second trimester~* willingness of voluntary interrupt the pregnancy~* comprehension of Italian Language~* baseline pain score ≥ 30 on a 100-mm visual analog pain scale (VAPS)~Exclusion Criteria:~* contraindication to epidural analgesia and to narcotics~* history of drug abuse or chronic use~* maternal disease (such as severe asthma, cardiac, liver or kidney disease)~* inability to comprehend or comply with the analgesia pain management procedures.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Programmed Intermittent Epidural Bolus (Type: ACTIVE_COMPARATOR): None
- Continuous Epidural Infusion (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~laboratories -and not subjects - will be randomized. All laboratories will start doing smears, when indicated by randomization, they will switch to Xpert MTB/Rif. There are no inclusion or exclusion criteria for the labs. Sputum specimens from non-diagnostic (follow up) patients, second samples for diagnostic tests, insufficient volume/visible blood specimens will be excluded from the Xpert testing.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xpert MTB/Rif (Type: EXPERIMENTAL): Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
- Sputum smear (Type: ACTIVE_COMPARATOR): Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient was previously diagnosed with multiple myeloma based on standard criteria and currently requires second or \*third line therapy because of PD, defined as a 25% increase in M-protein, or development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium \>11.5 mg/dL), or relapse from CR.\*Patients will only be eligible for bortezomib as 3rd line therapy if they have received dexamethasone alone, thalidomide alone (or with corticosteroids) or revlimid alone (or with corticosteroids) as one of the 2 prior therapies.~* Patient is of a legally consenting age, as defined by local regulations.~* Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.~* Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.~* Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.~* Male patient agrees to use an acceptable method for contraception for the duration of the study.~* Patient has measurable disease~* Patient has a Karnofsky performance status ≥60%.~* Patient has a life-expectancy \>3 months.~Exclusion Criteria:~* Primary Dexamethasone resistance~* Prior therapy with Bortezomib~* Prior severe allergic reactions to Bortezomib (Velcade), Boron or Mannitol~* Neuropathy \> Grade 2 with pain by NCI-CTCAE criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bortezomib and Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Tumor Shrinkage in Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* No previous treatment for acromegaly~Exclusion Criteria:~* primary surgery~* concomitant hyperprolactinemia requiring combined somatostatin analogues and dopamine-agonist treatment~* primary treatment with lanreotide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate.~* Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.~* Active disease as defined by both \>=6 tender or painful joints on motion and \>= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) \> 28 mm or a C-reactive protein (CRP) concentration \> 7 mg/dL~Exclusion Criteria:~* Blood dyscrasias including confirmed: Hemoglobin \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; Absolute neutrophil count \<1.2 x 109/L; Platelet count \<100 x 109/L~* History of any other rheumatic autoimmune disease other than Sjogren's syndrome~* No malignancy or history of malignancy~* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug~* No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg BID CP-690,550 (Type: EXPERIMENTAL): None
- 10 mg BID CP-690,550 (Type: EXPERIMENTAL): None
- methotrexate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is between 18-55 years of age, inclusive.~2. Subject meets the following criteria for a diagnosis of BED:~   * Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).~  * The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.~  * Marked distress regarding binge eating.~  * The binge eating occurs, on average, at least 2 days a week for 6 months.~  * The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.~3. Subject is consistently able to swallow a capsule.~Exclusion Criteria:~1. Subject has current diagnosis of bulimia nervosa or anorexia nervosa.~2. Subject is receiving psychotherapy or weight loss support within the past 3 months.~3. Subject has used psychostimulants to facilitate fasting or dieting within the past 6 months.~4. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease.~5. Subject has abnormal thyroid function.~6. Subject initiated treatment with a lipid lowering medication within the past 3 months.~7. Subject has a history of moderate or severe hypertension.~8. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder.~9. Subject has glaucoma.~10. Subject is female and pregnant or nursing.~11. Subjects who have had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine dimesylate (Type: EXPERIMENTAL): Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
- Placebo (Type: PLACEBO_COMPARATOR): Administer one capsule orally daily at approximately 7:00 AM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of SK-1403

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum PTH\>240 pg/mL at the screening~* Serum corrected Ca≧8.4 mg/dL at the screening~* Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration~Exclusion Criteria:~* Primary hyperparathyroidism~* Severe liver disease~* Severe Cardiac disease~* History or family history of long QT syndrome~* Malignant tumor~* Uncontrolled diabetes mellitus~* Uncontrolled hypertension~* History of severe drug allergy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SK-1403 (Type: EXPERIMENTAL): Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete